Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Johnson & Johnson Reports 77% Tumor Response Rate in Head and Neck Cancer Trial

Johnson & Johnson Reports 77% Tumor Response Rate in Head and Neck Cancer Trial

MT newswireMT newswire2026/10/26 08:35
04:35 AM EDT, 10/26/2026 (MT Newswires) -- Johnson & Johnson (JNJ) said late Sunday that its investigational Rybrevant Faspro combination achieved a 77% confirmed response rate in a phase 1b/2 study of patients with recurrent or metastatic head and neck cancer, excluding HPV-associated oropharyngeal cancer. The regimen achieved complete responses in 14% of the 22 patients, with 65% of responses ongoing at a median follow-up of 10.6 months. The median time to response was 9.4 weeks, and the one-year survival rate was 77%, the company said. The findings support further evaluation in the ongoing phase 3 OrigAMI-5 study. The most common side effects included anemia, low albumin levels, reduced platelet counts and mouth inflammation. Johnson & Johnson said an application for Rybrevant Faspro in later-line head and neck cancer is under Priority Review with the US Food and Drug Administration.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36

Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

智通财经•2026/11/05 01:07
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

The Senate takes control, the White House can no longer appoint "its own people", has the Federal Reserve's independence alarm been lifted?

After the Senate changed hands, the White House's room to install its own people at the Federal Reserve has been significantly narrowed. JPMorgan economist Feroli pointed out that the only expiring Federal Reserve Board position in the next two years is Powell's chairmanship (January 2028). If the White House wants to fill it, it must nominate a candidate acceptable to the Democratic-controlled Senate; otherwise, the seat will remain vacant. Meanwhile, the political value of removing Board member Cook has therefore diminished, and current Chair Waller's path to reappointment is also facing new congressional public relations pressure.

华尔街见闻•2026/11/05 00:41
The Senate takes control, the White House can no longer appoint "its own people", has the Federal Reserve's independence alarm been lifted?